Study of Ketamine and Perampanel Effects on Brain Receptors for Treating Resistant Depression

What this Trial Is About

Researchers are evaluating the combined effects of perampanel and ketamine on people with treatment-resistant depression. The study aims to test the idea that stimulating Alpha-Amino-3-Hydroxy-5-Methyl-4-Isoxazole Propionic Acid receptors AMPAR is important for ketamines anti-depressant response. This is the first human study to explore whether blocking AMPAR affects ketamines ability to reduce depression symptoms and influence brain activity. Participants will receive two treatments in a randomized, double-blind crossover design ketamine combined with either oral perampanel 6 mg or an oral placebo. Each treatment day includes a 2-hour MRI scan during ketamine infusion, followed by another scan and symptom assessments 24 hours later. The study includes a screening session to ensure safety for receiving these drugs. During the study, participants undergo physical exams, blood and urine tests, electrocardiograms, and drug and alcohol screenings. Researchers measure brain connectivity and oxygen metabolism during ketamine infusion and assess clinical improvement with depression rating scales 24 hours afterward. Safety monitoring continues throughout, and participants are advised not to drive or operate heavy machinery for 24 hours after infusion. The entire process involves two treatment days approximately 21 days apart.

Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response